(SHC) Sotera Health - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 4.466m USD | Total Return: 28.4% in 12m

Sterilization Services, Lab Testing, Radioactive Isotopes, Gamma
Total Rating 51
Safety 71
Buy Signal -0.20
Diagnostics & Research
Industry Rotation: +1.9
Market Cap: 4.47B
Avg Turnover: 52.0M
Risk 3d forecast
Volatility33.2%
VaR 5th Pctl5.38%
VaR vs Median-1.53%
Reward TTM
Sharpe Ratio0.78
Rel. Str. IBD36.4
Rel. Str. Peer Group60.3
Character TTM
Beta1.019
Beta Downside0.694
Hurst Exponent0.604
Drawdowns 3y
Max DD48.77%
CAGR/Max DD0.09
CAGR/Mean DD0.18
EPS (Earnings per Share) EPS (Earnings per Share) of SHC over the last years for every Quarter: "2021-03": 0.18, "2021-06": 0.26, "2021-09": 0.21, "2021-12": 0.23, "2022-03": 0.22, "2022-06": 0.27, "2022-09": 0.23, "2022-12": 0.25, "2023-03": 0.13, "2023-06": 0.08, "2023-09": 0.21, "2023-12": 0.26, "2024-03": 0.13, "2024-06": 0.19, "2024-09": 0.17, "2024-12": 0.21, "2025-03": 0.14, "2025-06": 0.2, "2025-09": 0.26, "2025-12": 0.26, "2026-03": 0.18,
EPS CAGR: 9.20%
EPS Trend: 80.1%
Last SUE: 0.64
Qual. Beats: 0
Revenue Revenue of SHC over the last years for every Quarter: 2021-03: 212.148, 2021-06: 251.917, 2021-09: 226.164, 2021-12: 241.249, 2022-03: 236.754, 2022-06: 266.639, 2022-09: 248.704, 2022-12: 251.59, 2023-03: 220.59, 2023-06: 255.282, 2023-09: 263.177, 2023-12: 310.239, 2024-03: 248.176, 2024-06: 276.594, 2024-09: 285.468, 2024-12: 290.203, 2025-03: 254.523, 2025-06: 294.341, 2025-09: 311.312, 2025-12: 303.441, 2026-03: 280.045,
Rev. CAGR: 6.47%
Rev. Trend: 94.2%
Last SUE: 1.50
Qual. Beats: 1

Warnings

Altman Z'' 0.78 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: SHC Sotera Health

Sotera Health Company (SHC) provides essential sterilization, lab testing, and advisory services for the global healthcare, pharmaceutical, and food safety industries. Operating through three specialized segments-Sterigenics, Nordion, and Nelson Labs-the company utilizes gamma irradiation, ethylene oxide, and electron beam technologies to ensure the safety and efficacy of medical devices and life sciences products.

As a provider of outsourced terminal sterilization, Sotera Health functions as a critical link in the medical supply chain, as approximately 90% of all medical device sterilization is performed using either ethylene oxide or gamma radiation. The company’s Nordion segment is a primary global supplier of Cobalt-60, a radioactive isotope essential for the gamma sterilization process and certain cancer treatments.

Investors may find it useful to evaluate the companys long-term contract structures and regulatory positioning on ValueRay. Headquartered in Ohio, the firm supports a broad international client base by providing microbiological testing and analytical chemistry services that assist manufacturers in meeting stringent global compliance standards.

Headlines to Watch Out For
  • Ethylene oxide litigation settlements and regulatory compliance costs impact long-term liability
  • Sterilization volume growth tracks global medical device and pharmaceutical manufacturing output
  • Cobalt-60 supply chain stability remains critical for Nordion segment revenue generation
  • Outsourced microbiological lab testing demand drives Nelson Labs margin expansion
  • Rising interest rates influence debt service costs for highly leveraged balance sheet
Piotroski VR-10 (Strict) 4.5
Net Income: 117.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.43 > 1.0
NWC/Revenue: 31.80% < 20% (prev 29.73%; Δ 2.08% < -1%)
CFO/TA 0.08 > 3% & CFO 259.1m > Net Income 117.8m
Net Debt (2.09b) to EBITDA (498.1m): 4.19 < 3
Current Ratio: 2.82 > 1.5 & < 3
Outstanding Shares: last quarter (287.6m) vs 12m ago 1.43% < -2%
Gross Margin: 55.01% > 18% (prev 0.55%; Δ 5.45k% > 0.5%)
Asset Turnover: 37.55% > 50% (prev 35.73%; Δ 1.82% > 0%)
Interest Coverage Ratio: 2.43 > 6 (EBITDA TTM 498.1m / Interest Expense TTM 149.6m)
Altman Z'' 0.78
A: 0.12 (Total Current Assets 586.0m - Total Current Liabilities 207.8m) / Total Assets 3.24b
B: -0.16 (Retained Earnings -505.5m / Total Assets 3.24b)
C: 0.11 (EBIT TTM 363.9m / Avg Total Assets 3.17b)
D: -0.24 (Book Value of Equity -628.6m / Total Liabilities 2.61b)
Altman-Z'' = 0.78 = B
Beneish M -2.98
DSRI: 1.07 (Receivables 176.3m/153.1m, Revenue 1.19b/1.11b)
GMI: 1.00 (GM 55.01% / 55.17%)
AQI: 0.96 (AQ_t 0.46 / AQ_t-1 0.47)
SGI: 1.07 (Revenue 1.19b / 1.11b)
TATA: -0.04 (NI 117.8m - CFO 259.1m) / TA 3.24b)
Beneish M = -2.98 (Cap -4..+1) = A
What is the price of SHC shares?

As of May 27, 2026, the stock is trading at USD 15.96 with a total of 3,068,790 shares traded.
Over the past week, the price has changed by +3.97%, over one month by +0.95%, over three months by -3.10% and over the past year by +28.40%.

Is SHC a buy, sell or hold?

Sotera Health has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy SHC.

  • StrongBuy: 3
  • Buy: 2
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the SHC price?
Analysts Target Price 20.1 26.1%
Sotera Health (SHC) - Fundamental Data Overview as of 26 May 2026
Market Cap USD = 4.47b (4.47b USD * 1.0 USD.USD)
P/E Trailing = 38.1951
P/E Forward = 15.6495
P/S = 3.7554
P/B = 7.1738
P/EG = 1.6829
Revenue TTM = 1.19b USD
EBIT TTM = 363.9m USD
EBITDA TTM = 498.1m USD
Long Term Debt = 2.12b USD (from longTermDebt, last quarter)
Short Term Debt = 23.3m USD (from shortTermDebt, last quarter)
Debt = 2.40b USD (from shortLongTermDebtTotal, last quarter) + Leases 131.9m
Net Debt = 2.09b USD (calculated: Debt 2.40b - CCE 315.9m)
Enterprise Value = 6.55b USD (4.47b + Debt 2.40b - CCE 315.9m)
Interest Coverage Ratio = 2.43 (Ebit TTM 363.9m / Interest Expense TTM 149.6m)
EV/FCF = 69.12x (Enterprise Value 6.55b / FCF TTM 94.8m)
FCF Yield = 1.45% (FCF TTM 94.8m / Enterprise Value 6.55b)
FCF Margin = 7.97% (FCF TTM 94.8m / Revenue TTM 1.19b)
Net Margin = 9.91% (Net Income TTM 117.8m / Revenue TTM 1.19b)
Gross Margin = 55.01% ((Revenue TTM 1.19b - Cost of Revenue TTM 535.0m) / Revenue TTM)
Gross Margin QoQ = 51.43% (prev 54.68%)
Tobins Q-Ratio = 2.02 (Enterprise Value 6.55b / Total Assets 3.24b)
Interest Expense / Debt = 6.23% (Interest Expense 149.6m / Debt 2.40b)
Taxrate = 37.60% (16.0m / 42.6m)
NOPAT = 227.1m (EBIT 363.9m * (1 - 37.60%))
Current Ratio = 2.82 (Total Current Assets 586.0m / Total Current Liabilities 207.8m)
Debt / Equity = 3.86 (Debt 2.40b / totalStockholderEquity, last quarter 622.5m)
Debt / EBITDA = 4.19 (Net Debt 2.09b / EBITDA 498.1m)
Debt / FCF = 22.01 (Net Debt 2.09b / FCF TTM 94.8m)
Total Stockholder Equity = 572.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.72% (Net Income 117.8m / Total Assets 3.24b)
RoE = 10.93% (Net Income TTM 117.8m / Total Stockholder Equity 1.08b)
RoCE = 11.36% (EBIT 363.9m / Capital Employed (Equity 1.08b + L.T.Debt 2.12b))
RoIC = 7.48% (NOPAT 227.1m / Invested Capital 3.03b)
WACC = 7.58% (E(4.47b)/V(6.87b) * Re(9.57%) + D(2.40b)/V(6.87b) * Rd(6.23%) * (1-Tc(0.38)))
Discount Rate = 9.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 0.67%
[DCF] Terminal Value 74.14% ; FCFF base≈98.5m ; Y1≈91.5m ; Y5≈83.0m
 [DCF] Fair Price = N/A (negative equity: EV 1.31b - Net Debt 2.09b = -772.4m; debt exceeds intrinsic value)
 EPS Correlation: 80.07 | EPS CAGR: 9.20% | SUE: 0.64 | # QB: 0
Revenue Correlation: 94.21 | Revenue CAGR: 6.47% | SUE: 1.50 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.24 | Chg30d=-1.67% | Revisions=-40% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.27 | Chg30d=+0.44% | Revisions=+20% | Analysts=10
EPS current Year (2026-12-31): EPS=0.97 | Chg30d=+0.74% | Revisions=+20% | GrowthEPS=+12.9% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=1.06 | Chg30d=+1.40% | Revisions=+33% | GrowthEPS=+9.3% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: -40%